This week, Peter Simons covers the latest news on the FDA's approval of failed Alzheimer's drug aducanumab, against the recommendation of its own advisory committee, which led to three members of the committee resigning in protest. He also covers an article confirming yet again that the FDA's black box warning that antidepressants can cause suicide did not increase suicides. Finally, he covers a study that reveals what exactly service users value about hearing voices groups, and why they are so important.

• FDA Approves Failed Drug Against Advisory Committee Recommendation
• No, the FDA’s Black Box Warning Did Not Increase Suicides
• Qualitative Study Highlights the Meaning and Impact of Hearing Voices Groups